Patient derived tumors
in the laboratory.
TumorGenesis is a global developer of world-class and innovative technologies using 3D cell culture and media. Specialists in developing technologies that preserve the patients’ derived cancer tissue biological signatures. Drivers of research to study cancer samples in the laboratory that reflect the tumors found in patients.
Our novel TumorGenesis tumor modeling could provide pharmaceutical companies newfound ability for more effective and expeditious drug development and subsequently improve patient outcomes.
We’re focused on providing the best media for the right cancer cell and sourcing those cancer cells from Patient Derived Tumors around the world.
A living library of ovarian cancer cells allows researches to study ovarian cancer in the laboratory setting that mimics the tumors found in the patient.
TumorGenesis was founded in 2018 and for the last two years has been working with its partners to advance the ovarian cancer cell culture media. Ovarian cancer is one of the leading causes for mortality with about 22,000 patient per year and a death rate of about 14,000 per year in the US alone. The standard of care for ovarian cancer patients is the use of cisplatin (or carboplatin) in combination with taxol. Following surgery, alternating weekly treatments with intraperitoneal and intravenous infusions of the two different drugs, one IV and the other IP, and alternating. Only 40-50% of women survived treatment and post-treatment (5 years). We first licensed in the media, and 11 of the 25 ovarian cancer cell lines were identified, thus representing 90%+ of all ovarian cancers.
The cancer cells accessible to researchers that use our media are available by request only from TumorGenesis Inc.
We are interested in collaborations where our media can be used in existing grants as well as our new discovery kits for identifying surface markers on ovarian cancer samples from around the world. If your research grants can use our media’s and discovery kits, contact us here.